ERG and prostate cancer: Similar to our observation, Stumm et al. reported moderate to strong FOXP2 protein expression in 75% of prostate tumors, and a higher protein expression level of FOXP2 was correlated with higher Gleason score, advanced T stage, and earlier cancer recurrence in ERG fusion-negative prostate cancers (Stumm et al., 2013).